SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-24-000125
Filing Date
2024-05-31
Accepted
2024-05-31 16:01:52
Documents
13
Period of Report
2024-05-31
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20240531.htm   iXBRL 8-K 42581
  Complete submission text file 0001714899-24-000125.txt   166616

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240531.xsd EX-101.SCH 1934
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240531_lab.xml EX-101.LAB 21629
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240531_pre.xml EX-101.PRE 12530
16 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240531_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 241009517
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)